Chikungunya Virus Strains Show Lineage-Specific Varia
Cross-Protective Ability in Murine and Nonhuman Prim

MBio

9,

DOI: 10.1128/mbio.02449-17

Citation Report

#	Article	IF	Citations
1	Cellular and Molecular Immune Response to Chikungunya Virus Infection. Frontiers in Cellular and Infection Microbiology, 2018, 8, 345.	3.9	61
2	A recombinant virus vaccine that protects against both Chikungunya and Zika virus infections. Vaccine, 2018, 36, 3894-3900.	3.8	35
3	Chikungunya Virus Vaccines: Platforms, Progress, and Challenges. Current Topics in Microbiology and Immunology, 2019, , 1.	1.1	11
4	Establishment and Comparison of Pathogenicity and Related Neurotropism in Two Age Groups of Immune Competent Mice, C57BL/6J Using an Indian Isolate of Chikungunya Virus (CHIKV). Viruses, 2019, 11, 578.	3.3	6
5	Visualization of chikungunya virus infection in vitro and in vivo. Emerging Microbes and Infections, 2019, 8, 1574-1583.	6.5	12
6	Whole Transcriptome Analysis of Aedes albopictus Mosquito Head and Thorax Post-Chikungunya Virus Infection. Pathogens, 2019, 8, 132.	2.8	10
7	Rheumatic manifestations of chikungunya: emerging concepts and interventions. Nature Reviews Rheumatology, 2019, 15, 597-611.	8.0	117
8	Updated Phylogeny of Chikungunya Virus Suggests Lineage-Specific RNA Architecture. Viruses, 2019, 11, 798.	3.3	32
9	Characterization of antibody response in patients with acute and chronic chikungunya virus disease. Journal of Clinical Virology, 2019, 117, 68-72.	3.1	7
10	Immunogenicity and Efficacy of a Measles Virus-Vectored Chikungunya Vaccine in Nonhuman Primates. Journal of Infectious Diseases, 2019, 220, 735-742.	4.0	45
11	Arthritogenic Alphaviruses: A Worldwide Emerging Threat?. Microorganisms, 2019, 7, 133.	3.6	56
12	An adjuvanted adenovirus 5-based vaccine elicits neutralizing antibodies and protects mice against chikungunya virus-induced footpad swelling. Vaccine, 2019, 37, 3146-3150.	3.8	13
13	Evaluation of medicinal herbs for Anti-CHIKV activity.. Virology, 2019, 533, 45-49.	2.4	21
14	51 years in of Chikungunya clinical vaccine development: A historical perspective. Human Vaccines and Immunotherapeutics, 2019, 15, 2351-2358.	3.3	20
15	A Single and Un-Adjuvanted Dose of a Chimpanzee Adenovirus-Vectored Vaccine against Chikungunya Virus Fully Protects Mice from Lethal Disease. Pathogens, 2019, 8, 231.	2.8	21
16	Recent Progress in Vaccine Development Against Chikungunya Virus. Frontiers in Microbiology, 2019, 10, 2881.	3.5	49
17	Epidemiological Evidence for Lineage-Specific Differences in the Risk of Inapparent Chikungunya Virus Infection. Journal of Virology, 2019, 93, .	3.4	37
18	Chikungunya as a paradigm for emerging viral diseases: Evaluating disease impact and hurdles to vaccine development. PLoS Neglected Tropical Diseases, 2019, 13, e0006919.	3.0	71

#	Article	IF	Citations
19	The Potential Impact of Chikungunya Virus Outbreaks on Blood Transfusion. Transfusion Medicine Reviews, 2020, 34, 23-28.	2.0	7
20	DDX56 Binds to Chikungunya Virus RNA To Control Infection. MBio, 2020, 11, .	4.1	15
21	Epidemic Alphaviruses: Ecology, Emergence and Outbreaks. Microorganisms, 2020, 8, 1167.	3.6	28
22	Strain-dependent disease and response to favipiravir treatment in mice infected with Chikungunya virus. Antiviral Research, 2020, 182, 104904.	4.1	9
23	Rationally Attenuated Vaccines for Venezuelan Equine Encephalitis Protect Against Epidemic Strains with a Single Dose. Vaccines, 2020, 8, 497.	4.4	6
24	Effects of Mosquito Biology on Modeled Chikungunya Virus Invasion Potential in Florida. Viruses, 2020, 12, 830.	3.3	1
25	Adenoviral-Vectored Mayaro and Chikungunya Virus Vaccine Candidates Afford Partial Cross-Protection From Lethal Challenge in A129 Mouse Model. Frontiers in Immunology, 2020, 11, 591885.	4.8	19
26	Arthritogenic Alphavirus Vaccines: Serogrouping Versus Cross-Protection in Mouse Models. Vaccines, 2020, 8, 209.	4.4	21
27	Transmission of Chikungunya Virus in an Urban Slum, Brazil. Emerging Infectious Diseases, 2020, 26, 1364-1373.	4.3	21
28	The vaccinia virus based Sementis Copenhagen Vector vaccine against Zika and chikungunya is immunogenic in non-human primates. Npj Vaccines, 2020, 5, 44.	6.0	17
29	Pathogenetic Potential Relating to Metabolic Activity in a Mouse Model of Infection with the Chikungunya Virus East/Central/South African Genotype. Viruses, 2020, 12, 169.	3.3	5
30	Current Efforts in the Development of Vaccines for the Prevention of Zika and Chikungunya Virus Infections. Frontiers in Immunology, 2020, 11, 592.	4.8	34
31	Arboviruses related with chronic musculoskeletal symptoms. Best Practice and Research in Clinical Rheumatology, 2020, 34, 101502.	3.3	10
32	Chikungunya, Dengue, Zika, and Other Emerging Mosquito-Borne Viruses. Neglected Tropical Diseases, 2021, , 157-196.	0.4	1
33	Prophylactic strategies to control chikungunya virus infection. Virus Genes, 2021, 57, 133-150.	1.6	6
34	Discriminating arboviral species. Journal of General Virology, 2021, 102, .	2.9	1
35	The Putative Roles and Functions of Indel, Repetition and Duplication Events in Alphavirus Non-Structural Protein 3 Hypervariable Domain (nsP3 HVD) in Evolution, Viability and Re-Emergence. Viruses, 2021, 13, 1021.	3.3	3
36	Molecular techniques for the genomic viral RNA detection of West Nile, Dengue, Zika and Chikungunya arboviruses: a narrative review. Expert Review of Molecular Diagnostics, 2021, 21, 591-612.	3.1	5

#	Article	IF	Citations
37	The utilization of advance telemetry to investigate critical physiological parameters including electroencephalography in cynomolgus macaques following aerosol challenge with eastern equine encephalitis virus. PLoS Neglected Tropical Diseases, 2021, 15, e0009424.	3.0	6
38	A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial. Nature Communications, 2021, 12, 4636.	12.8	31
39	Chikungunya virus molecular evolution in India since its re-emergence in 2005. Virus Evolution, 2021, 7, veab074.	4.9	3
40	Defining Efficacy of Chikungunya Virus Candidate Vaccines: Different Endpoints Derived From the Virusâ€"Cytokineâ€"Ferritin (VCF) Model. Frontiers in Virology, 2021, 1, .	1.4	1
41	Alphavirus Virulence Determinants. Pathogens, 2021, 10, 981.	2.8	6
42	Therapeutic alphavirus cross-reactive E1 human antibodies inhibit viral egress. Cell, 2021, 184, 4430-4446.e22.	28.9	25
43	A Mouse Model for Studying Post-Acute Arthritis of Chikungunya. Microorganisms, 2021, 9, 1998.	3.6	5
44	Antibody effector analysis of prime versus prime-boost immunizations with a recombinant measles-vectored chikungunya virus vaccine. JCI Insight, 2021, 6, .	5.0	10
45	Chikungunya and arthritis: An overview. Travel Medicine and Infectious Disease, 2021, 44, 102168.	3.0	22
46	Population bottlenecks and founder effects: implications for mosquito-borne arboviral emergence. Nature Reviews Microbiology, 2021, 19, 184-195.	28.6	51
47	Chikungunya Outbreaks in India: A Prospective Study Comparing Neutralization and Sequelae during Two Outbreaks in 2010 and 2016. American Journal of Tropical Medicine and Hygiene, 2020, 102, 857-868.	1.4	11
48	Isolation and characterization of high affinity and highly stable anti-Chikungunya virus antibodies using ALTHEA Gold Librariesâ„¢. BMC Infectious Diseases, 2021, 21, 1121.	2.9	2
50	Chikungunya infection: de-linking replication from symptomatology reveals the central role of muscle. Journal of Clinical Investigation, 2020, 130, 1099-1101.	8.2	0
51	Chikungunya Case Classification after the Experience with Dengue Classification: How Much Time Will We Lose?. American Journal of Tropical Medicine and Hygiene, 2020, 102, 257-259.	1.4	3
52	Immunogenic properties of the preparation containing the Chikungunya virus antigen inactivated by Î²-propiolactone. Zhurnal Mikrobiologii Epidemiologii I Immunobiologii, 2021, 98, 519-527.	1.0	0
53	Seroprevalence of chikungunya virus among military personnel in Papua New Guinea, 2019. IJID Regions, 2022, 3, 34-36.	1.3	1
54	Immunological implications of diverse production approaches for Chikungunya virus-like particle vaccines. Vaccine, 2022, , .	3.8	2
55	A Review on Chikungunya Virus Epidemiology, Pathogenesis and Current Vaccine Development. Viruses, 2022, 14, 969.	3.3	45

#	Article	IF	Citations
56	Aedes aegypti Aag-2 Cell Proteome Modulation in Response to Chikungunya Virus Infection. Frontiers in Cellular and Infection Microbiology, 0, 12, .	3.9	3
57	Exploring potential anti-chikungunya virus activity of phytocompounds: Computational docking and in vitro studies. Journal of King Saud University - Science, 2022, 34, 102157.	3.5	2
58	Changing spectrum of acute encephalitis syndrome in India and a syndromic approach. Annals of Indian Academy of Neurology, 2022, 25, 354.	0.5	4
59	The origin and continuing adaptive evolution of chikungunya virus. Archives of Virology, 2022, 167, 2443-2455.	2.1	6
60	Animal models of alphavirus infection and human disease. Advances in Virus Research, 2022, , 25-88.	2.1	2
61	Vaccines against Emerging and Neglected Infectious Diseases: An Overview. Vaccines, 2022, 10, 1385.	4.4	8
62	Chikungunya Vaccine Candidates: Current Landscape and Future Prospects. Drug Design, Development and Therapy, 0, Volume 16, 3663-3673.	4.3	11
63	Generation of a Live-Attenuated Strain of Chikungunya Virus from an Indian Isolate for Vaccine Development. Vaccines, 2022, 10, 1939.	4.4	2
64	Chikungunya: risks for travellers. Journal of Travel Medicine, 2023, 30, .	3.0	11
65	Understanding the Biology and Immune Pathogenesis of Chikungunya Virus Infection for Diagnostic and Vaccine Development. Viruses, 2023, 15, 48.	3.3	2
66	Construction and immunogenicity of an mRNA vaccine against chikungunya virus. Frontiers in Immunology, 0, 14, .	4.8	1
67	Prevalence of Barmah Forest Virus, Chikungunya Virus and Ross River Virus Antibodies among Papua New Guinea Military Personnel before 2019. Viruses, 2023, 15, 394.	3.3	1
68	Evolution and immunopathology of chikungunya virus informs therapeutic development. DMM Disease Models and Mechanisms, 2023, 16, .	2.4	2
69	Chikungunya vaccines: advances in the development and prospects for marketing approval. BIOpreparations Prevention Diagnosis Treatment, 2023, 23, 42-64.	0.5	0
70	Congenital Chikungunya Virus Infections. , 2023, 2, 45-59.		1
71	Replication and innate immune responses of two chikungunya virus genotypes in human monocyte-derived macrophages. Journal of General Virology, 2023, 104, .	2.9	1
72	Effect of Viral Strain and Host Age on Clinical Disease and Viral Replication in Immunocompetent Mouse Models of Chikungunya Encephalomyelitis. Viruses, 2023, 15, 1057.	3.3	2
73	Tropism and immune response of chikungunya and zika viruses: An overview. Cytokine, 2023, 170, 156327.	3.2	0

#	Article	IF	Citations
74	New Vaccines on the Immediate Horizon for Travelers: Chikungunya and Dengue Vaccines. Current Infectious Disease Reports, 2023, 25, 211-224.	3.0	2
75	Development of Therapeutic Monoclonal Antibodies for Emerging Arbovirus Infections. Viruses, 2023, 15, 2177.	3.3	0
76	Dynamics of chikungunya virus transmission in the first year after its introduction in Brazil: A cohort study in an urban community. PLoS Neglected Tropical Diseases, 2023, 17, e0011863.	3.0	1
77	Chikungunya: a decade of burden in the Americas. The Lancet Regional Health Americas, 2024, 30, 100673.	2.6	0
78	Immunogenicity, safety and duration of protection afforded by chikungunya virus vaccines undergoing human clinical trials. Journal of General Virology, 2024, 105, .	2.9	0
79	Potential Serological Misdiagnosis of Barmah Forest Virus and Ross River Virus Diseases as Chikungunya Virus Infections in Australia: Comparison of ELISA with Neutralization Assay Results. Viruses, 2024, 16, 384.	3.3	0